Adam A Garsa1, Albert J Chang1, Todd Dewees1, Christopher R Spencer1, Douglas R Adkins2, Farrokh Dehdashti3, Hiram A Gay1, Wade L Thorstad1. 1. Department of Radiation Oncology; Siteman Cancer Center, Barnes-Jewish Hospital and Washington University, School of Medicine, 4921 Parkview Place, Lower Level, St., Louis, MO 63110, USA. 2. Department of Medicine; Siteman Cancer Center, Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, MO 63110, USA. 3. Division of Nuclear Medicine, Mallinckrodt Institute of Radiology; Siteman Cancer Center, Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, MO 63110, USA.
Abstract
OBJECTIVE: To evaluate whether pretreatment metabolic parameters obtained from positron emission tomography (PET) with [18F]fluorodeoxyglucose (FDG) can improve risk prediction for patients with oropharyngeal squamous cell carcinoma (OPSCC) treated with definitive intensity-modulated radiation therapy (IMRT). METHODS: Between 2003 and 2009, 86 patients with OPSCC had FDG-PET/CT prior to treatment with definitive IMRT. Chemotherapy was administered to 90 % of the patients. Metabolic tumor volume (MTV), total lesion glycolysis (TLG), maximum standardized uptake value (SUVmax), mean SUV (SUVmean), and inverse coefficient of variation (1/CoV) were analyzed for the primary tumor alone and the total of the primary tumor and involved lymph nodes. RESULTS: Median follow-up time for surviving patients was 41 months. On univariate analysis, total MTV and total TLG were significant predictors of disease-free survival (DFS) and overall survival (OS). SUVmax, SUVmean, and 1/CoV failed to predict DFS or OS. On multivariate analysis controlling for T- and N-classification, total MTV remained a significant predictor of DFS and OS. The optimal cutpoint for total MTV was 20.5 ml. A total MTV >20.5 ml was associated with a 4.13-fold increased risk of death (95 % confidence interval [CI], 2.12-8.05; p < 0.0001). Total MTV remained a significant predictor of DFS and OS for the subgroups with p16-positive (n = 25) and p16-negative (n = 18) cancer. CONCLUSION: Total MTV is an independent predictor of DFS and OS for patients with OPSCC treated with definitive radiotherapy. Total MTV remained predictive of DFS and OS for both p16-positive and p16-negative cancer.
OBJECTIVE: To evaluate whether pretreatment metabolic parameters obtained from positron emission tomography (PET) with [18F]fluorodeoxyglucose (FDG) can improve risk prediction for patients with oropharyngeal squamous cell carcinoma (OPSCC) treated with definitive intensity-modulated radiation therapy (IMRT). METHODS: Between 2003 and 2009, 86 patients with OPSCC had FDG-PET/CT prior to treatment with definitive IMRT. Chemotherapy was administered to 90 % of the patients. Metabolic tumor volume (MTV), total lesion glycolysis (TLG), maximum standardized uptake value (SUVmax), mean SUV (SUVmean), and inverse coefficient of variation (1/CoV) were analyzed for the primary tumor alone and the total of the primary tumor and involved lymph nodes. RESULTS: Median follow-up time for surviving patients was 41 months. On univariate analysis, total MTV and total TLG were significant predictors of disease-free survival (DFS) and overall survival (OS). SUVmax, SUVmean, and 1/CoV failed to predict DFS or OS. On multivariate analysis controlling for T- and N-classification, total MTV remained a significant predictor of DFS and OS. The optimal cutpoint for total MTV was 20.5 ml. A total MTV >20.5 ml was associated with a 4.13-fold increased risk of death (95 % confidence interval [CI], 2.12-8.05; p < 0.0001). Total MTV remained a significant predictor of DFS and OS for the subgroups with p16-positive (n = 25) and p16-negative (n = 18) cancer. CONCLUSION: Total MTV is an independent predictor of DFS and OS for patients with OPSCC treated with definitive radiotherapy. Total MTV remained predictive of DFS and OS for both p16-positive and p16-negative cancer.
Authors: David L Schwartz; Joseph Rajendran; Bevan Yueh; Marc D Coltrera; Michael Leblanc; Janet Eary; Kenneth Krohn Journal: Arch Otolaryngol Head Neck Surg Date: 2004-12
Authors: M R Posner; J H Lorch; O Goloubeva; M Tan; L M Schumaker; N J Sarlis; R I Haddad; K J Cullen Journal: Ann Oncol Date: 2011-02-11 Impact factor: 32.976
Authors: Steven M. Larson; Yusuf Erdi; Timothy Akhurst; Madhu Mazumdar; Homer A. Macapinlac; Ronald D. Finn; Cecille Casilla; Melissa Fazzari; Neil Srivastava; Henry W.D. Yeung; John L. Humm; Jose Guillem; Robert Downey; Martin Karpeh; Alfred E. Cohen; Robert Ginsberg Journal: Clin Positron Imaging Date: 1999-05
Authors: Trang H La; Edith J Filion; Brit B Turnbull; Jackie N Chu; Percy Lee; Khoa Nguyen; Peter Maxim; Andy Quon; Edward E Graves; Billy W Loo; Quynh-Thu Le Journal: Int J Radiat Oncol Biol Phys Date: 2009-03-14 Impact factor: 7.038
Authors: Dominic A X Schinagl; Wouter V Vogel; Aswin L Hoffmann; Jorn A van Dalen; Wim J Oyen; Johannes H A M Kaanders Journal: Int J Radiat Oncol Biol Phys Date: 2007-11-15 Impact factor: 7.038
Authors: Young Mi Seol; Bo Ran Kwon; Moo Kon Song; Young Jin Choi; Ho Jin Shin; Joo Seop Chung; Goon Jae Cho; Jin Chun Lee; Byung Joo Lee; Soo Geun Wang; Hak Jin Kim; Won Taek Kim; Seung Jang Kim; Eun Young Yun Journal: Acta Oncol Date: 2010 Impact factor: 4.089
Authors: Jon Cacicedo; Arturo Navarro; Olga Del Hoyo; Alfonso Gomez-Iturriaga; Filippo Alongi; Jose A Medina; Olgun Elicin; Andrea Skanjeti; Francesco Giammarile; Pedro Bilbao; Francisco Casquero; Berardino de Bari; Alan Dal Pra Journal: Br J Radiol Date: 2016-08-02 Impact factor: 3.039
Authors: Kai C C Johnson; Jessica Ley; Peter Oppelt; Jingxia Lu; Hiram A Gay; Mackenzie Daly; Ryan Jackson; Jason Rich; Patrik Pipkorn; Randal C Paniello; Jose Zevallos; Wade Thorstad; Douglas R Adkins Journal: Med Oncol Date: 2019-10-08 Impact factor: 3.064
Authors: Michael R Folkert; Jeremy Setton; Aditya P Apte; Milan Grkovski; Robert J Young; Heiko Schöder; Wade L Thorstad; Nancy Y Lee; Joseph O Deasy; Jung Hun Oh Journal: Phys Med Biol Date: 2017-06-12 Impact factor: 3.609
Authors: J Cacicedo; I Fernandez; O Del Hoyo; A Navarro; A Gomez-Iturriaga; J Ignacio Pijoan; L Martinez-Indart; J Escudero; J Gomez-Suarez; R Ortiz de Zarate; J Fernando Perez; P Bilbao; D Rades Journal: Clin Transl Oncol Date: 2017-05-24 Impact factor: 3.405
Authors: Maria Schwabe; Stanislav Spiridonov; Elizabeth L Yanik; Jack W Jennings; Travis Hillen; Maria Ponisio; Douglas J McDonald; Farrokh Dehdashti; Cara A Cipriano Journal: Sarcoma Date: 2019-07-01